Your search for oral corticosteroids returned 46 results

NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.

Study authors evaluated the impact on compliance and SNOT-20 scores in patients with allergic rhinitis using a novel sinus nasal rinse device.

In their presentation, Ahmad R. Sedaghat, MD, PhD and Stacey T. Gray, MD, FACS discuss both patient and physician perspectives for successful control of CRS.

Study authors conducted a prospective randomized trial to determine if there is a role for oral steroids in patients who have CRSsNP.

The most common presenting complaints included shortness of breath, rhinorrhea, and hoarseness.

Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.

Findings may help with decision-making in this high-risk patient population.

The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…

The BLA submission included data from the pivotal phase 3 NAVIGATOR trial that assessed tezepelumab in 1061 patients with severe, uncontrolled asthma.

Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine